Related Experiment Video
Updated: May 20, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations
Juan Manuel Rius-Peris1,2,3, Enrique Palomo-Atance4, Eva Muro-Díaz5
1Hospital Universitario Virgen de la Luz, Cuenca, Spain.
Aim:
This work was performed to assess the impact of nirsevimab immunisation on acute bronchiolitis hospitalisations during nearly the entire 2023-2024 epidemic year.
Methods:
An observational, multicentre, prospective study was conducted from 1 September 2021 to 15 June 2024 across 20 hospitals in two Spanish regions. Infants up to 12 months old admitted for acute bronchiolitis were included. Demographic, clinical and microbiological data were analysed across three epidemic years (2021-2022, 2022-2023 and 2023-2024). Statistical analyses were performed to evaluate the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV)-associated hospitalisations.
Results:
In total, 2656 patients were included. Bronchiolitis hospitalisations significantly declined in the post-nirsevimab epidemic year compared with previous years. The 2023-2024 season displayed a bimodal distribution, with the first peak dominated by RSV cases and the second by rhinoviruses and metapneumovirus. The proportion of RSV-associated bronchiolitis hospitalisations decreased by 20%-30%, while rhinovirus- and metapneumovirus-associated bronchiolitis cases increased by 10%-20%. The effectiveness of nirsevimab in preventing RSV-associated admissions was estimated to be approximately 70%.
Conclusion:
Nirsevimab immunisation significantly reduced RSV-associated bronchiolitis admissions, though an increase in rhinovirus- and metapneumovirus-associated cases was observed.
More Related Videos
Related Concept Videos
Vaccinations
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:

